JPS6049256B2 - Shiyaku for protein analysis - Google Patents
Shiyaku for protein analysisInfo
- Publication number
- JPS6049256B2 JPS6049256B2 JP14576879A JP14576879A JPS6049256B2 JP S6049256 B2 JPS6049256 B2 JP S6049256B2 JP 14576879 A JP14576879 A JP 14576879A JP 14576879 A JP14576879 A JP 14576879A JP S6049256 B2 JPS6049256 B2 JP S6049256B2
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- protein
- sample
- absorbance
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000004169 proteins and genes Human genes 0.000 title claims description 84
- 108090000623 proteins and genes Proteins 0.000 title claims description 84
- 238000004458 analytical method Methods 0.000 title claims description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 90
- 229920000609 methyl cellulose Polymers 0.000 claims description 15
- 239000001923 methylcellulose Substances 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000002835 absorbance Methods 0.000 description 47
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 22
- 108091006905 Human Serum Albumin Proteins 0.000 description 19
- 102000008100 Human Serum Albumin Human genes 0.000 description 19
- 238000011088 calibration curve Methods 0.000 description 19
- 238000010521 absorption reaction Methods 0.000 description 17
- 238000003756 stirring Methods 0.000 description 15
- 239000003085 diluting agent Substances 0.000 description 12
- 239000000975 dye Substances 0.000 description 11
- 239000011259 mixed solution Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 8
- 235000006408 oxalic acid Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- 108010074605 gamma-Globulins Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 4
- 239000011546 protein dye Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 229960005215 dichloroacetic acid Drugs 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- QYHFIVBSNOWOCQ-UHFFFAOYSA-N selenic acid Chemical compound O[Se](O)(=O)=O QYHFIVBSNOWOCQ-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108010038061 Chymotrypsinogen Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- -1 etc. are preferred Chemical compound 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000010151 yanghe Substances 0.000 description 1
Landscapes
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Description
【発明の詳細な説明】 本発明は蛋白質分析用試薬に関する。[Detailed description of the invention] The present invention relates to a reagent for protein analysis.
従来蛋白質分析用試薬としては特開昭53−2549吋
公報に記載された試薬が知られいる。As a conventional reagent for protein analysis, a reagent described in Japanese Unexamined Patent Publication No. 53-2549 is known.
斯・かる蛋白質分析用試薬は式で表わされる染料とPK
aO〜4の酸とからなるものである。This reagent for protein analysis consists of a dye represented by the formula and PK
It consists of an acid of aO~4.
該試薬はそれ自身茶褐色を呈しているが、該試薬と蛋白
質を含有するサンプルとを混合すると式(1)で表わさ
れる染料が蛋白質と結合して混合液は青色に変色する。
そしてその混合液の呈色度合を吸光度によつて求めその
値からサンプル中に含有される蛋白質の量を測定しよう
とするものである。しかしながら特開昭53−2549
0号公報に記載の蛋白質分析用試薬には下記(1)〜(
3)に示す難点がある。(1)式(1)で表わされる染
料と蛋白質とが結合して得られる蛋白質一染料錯体を含
む混合液は安定性に乏しく、時間の経過と共に混合液の
呈色度合が変化し、その為に蛋白質分析用試薬とサンプ
ルとを混合してから何分後に吸光度を測定するかによつ
て測定される蛋白質量が異な.り、サンプル中に含有さ
れている蛋白質の量を正確に定量するのが困難になる。The reagent itself has a brownish color, but when the reagent and a sample containing protein are mixed, the dye represented by formula (1) binds to the protein and the mixture turns blue.
Then, the degree of coloration of the mixed solution is determined by absorbance, and the amount of protein contained in the sample is measured from that value. However, JP-A-53-2549
The protein analysis reagents described in Publication No. 0 include the following (1) to (
There are drawbacks shown in 3). (1) A mixture containing a protein-dye complex obtained by combining the dye represented by formula (1) with a protein has poor stability, and the degree of coloration of the mixture changes over time. The amount of protein measured differs depending on how many minutes after mixing the protein analysis reagent and sample, the absorbance is measured. This makes it difficult to accurately quantify the amount of protein contained in a sample.
(2)蛋白質分析用試薬とサンプルとを混合する際の撹
拌又は振盪の程度により混合液の呈色度合が異なりそれ
故吸光度も異なつてくる。(2) Depending on the degree of stirring or shaking when mixing the protein analysis reagent and the sample, the degree of coloration of the mixed solution will vary, and therefore the absorbance will also vary.
これは!攪拌又は振盪条件を常に一定に維持することに
より解消し得るように思われるが、測定者の間に個人差
もあり攪拌又は振盪条件を常に一定に保つことは困難で
ある。その為に蛋白質の量を正確に定量するのが困難に
なる。 4(3)蛋白質分析用試薬は広範囲
の異なる蛋白質に感応するが、その感応の程度(感度)
には大小のばらつきがあり、そのために吸光度と蛋白質
量との関係を示す検量線の傾きは各種蛋白質にダ より
異なソー定していない。それ故サンプル中に含まれてい
る蛋白質が一種でありしかもその蛋白質種が明らかであ
る場合には、その蛋白質を用いて予め作成した検量線か
らサンプル中に含有されている蛋白質量を精度よく定量
し得るノ が、サンプル中に含まれている蛋白質が二種
以上である場合やサンプル中に含まれている蛋白質が一
種てあつてもその蛋白質種が不明である場合には、各種
蛋白質を用いて作成される種々の検量線のうちどの検量
線を基準に定めるかによつて、決定されるべきサンプル
中の蛋白質量が異なり、精度よく蛋白質を定量すること
が困難になる。このように特開昭53−2549吟公報
に記載の蛋白質分析用試薬には種々の難点があり、それ
らの難点を有さない蛋白質分析用試薬の開発が望まれて
いるのが現状である。this is! It seems that this problem can be solved by always keeping the stirring or shaking conditions constant, but it is difficult to keep the stirring or shaking conditions constant because of the individual differences among the measurers. This makes it difficult to accurately quantify the amount of protein. 4(3) Protein analysis reagents are sensitive to a wide range of different proteins, but the degree of sensitivity (sensitivity)
There are variations in size, and for this reason, the slope of the calibration curve showing the relationship between absorbance and protein amount is not determined depending on the type of protein. Therefore, if a sample contains only one type of protein and the type of protein is known, the amount of protein contained in the sample can be accurately quantified using a calibration curve prepared in advance using that protein. However, if the sample contains two or more types of proteins, or if the sample contains one protein but the type of protein is unknown, use various proteins. The amount of protein in a sample to be determined differs depending on which of the various calibration curves created by the method is used as a standard, making it difficult to accurately quantify protein. As described above, the reagent for protein analysis described in Japanese Patent Application Laid-Open No. 53-2549 has various drawbacks, and it is currently desired to develop a reagent for protein analysis that does not have these drawbacks.
本発明者らは斯かる現状に鑑み上記(1)〜(3)の難
点を有することのない蛋白質分析用試薬を開発すべく鋭
意研究を重ねてきた。In view of the current situation, the present inventors have conducted extensive research in order to develop a reagent for protein analysis that does not have the above-mentioned disadvantages (1) to (3).
その結果上記式(1)で表わされる染料と酸とからなる
混合物にメチルセルロースを配合した場合に所望の蛋白
質分析用試薬が得られることを見い出した。本発明は斯
かる知見に基づき完成されたものてある。本発明の蛋白
質分析用試薬は、特開昭53−254(社)号公報に記
載の蛋白質分析用試薬の有する利点をそのまま保持し、
しかも該試薬の有する上記(1)〜(3)の難点を解消
したものてある。即ち本発明試薬は、サンプル中に共存
する物質の影響を受けにくく、サンプル中に含有される
各種蛋白質を再現性よく優れた検出感度で定量すること
ができる。また本発明試薬とサンプルとを混合して生成
する蛋白質一染料錯体を含む混合液は極めて安定である
。従つて本発明試薬とサンプルとを混合してから3時間
経過した場合においてもサンプル中二に含有されている
蛋白質の量を正確に定量し得る。また本発明試薬を使用
することにより臨床検査上要求される大量のサンプル処
理が可能になる。また本発明試薬とサンプルとを混合す
る際の攪拌又は振盪条件が変化しても混合液の呈色度合
1は極めて変化を受けにくく、その為に吸光度も一定し
ている。従つて本発明試薬とサンプルとを混合する際の
攪拌又は振盪条件が異なつた場合においてもサンプル中
に含有されている蛋白質の量を正確に測定することがで
きる。さらに本発明試薬5は、広範囲の異なる蛋白質の
いずれにも感応し、しかも各種蛋白質に対する感度もよ
く一定しており、そのために各種蛋白質の検量線の傾き
は極めて近似している。それ故サンプル中に含まれてい
る蛋白質が一種てありしかもその蛋白質が明らか4であ
る場合は勿論のこと、サンプル中に含まれている蛋白質
が二種以上である場合やサンプル中に含まれている蛋白
質の種類が不明である場合においても、サンプル中の総
蛋白質量を精度よく測定し得る。加えて本発明試薬自身
の吸収曲線を測定したときの蛋白質測定波長での吸光度
(ブランク値)は低く、そそのためにサンプル中の蛋白
質含有量が多い場合においてもシングルビームの比色計
を使用できる。本発明試薬は上述した通り種々の利点を
有し、その為特に蛋白質が低濃度で含有されているサン
プルを定量した場合にも極めて良好な結果を得ることが
できる。本発明試薬において色調を変化させる活性成分
は上記式(1)て表わされる公知の染料即ちクーマシイ
ブリリアント ブルー(COOmassjeBril
ljantB]Ue)G−250である。As a result, it was found that a desired reagent for protein analysis can be obtained when methylcellulose is blended into a mixture consisting of a dye represented by the above formula (1) and an acid. The present invention has been completed based on this knowledge. The reagent for protein analysis of the present invention retains the advantages of the reagent for protein analysis described in JP-A-53-254,
Moreover, the above-mentioned disadvantages (1) to (3) of the reagent are solved. That is, the reagent of the present invention is not easily influenced by substances coexisting in the sample, and can quantify various proteins contained in the sample with good reproducibility and excellent detection sensitivity. Furthermore, a mixed solution containing a protein-dye complex produced by mixing the reagent of the present invention and a sample is extremely stable. Therefore, even if 3 hours have passed since the reagent of the present invention and the sample were mixed, the amount of protein contained in the sample can be accurately quantified. Furthermore, by using the reagent of the present invention, it becomes possible to process large quantities of samples required for clinical testing. Further, even if the stirring or shaking conditions when mixing the reagent of the present invention and the sample change, the degree of coloration 1 of the mixed liquid is extremely difficult to change, and therefore the absorbance is also constant. Therefore, even if the stirring or shaking conditions used when mixing the reagent of the present invention and the sample are different, the amount of protein contained in the sample can be accurately measured. Furthermore, the reagent 5 of the present invention is sensitive to all of a wide range of different proteins, and its sensitivity to various proteins is also well constant, so that the slopes of the calibration curves for various proteins are extremely similar. Therefore, it goes without saying that there is only one type of protein contained in the sample and that protein is clearly 4, but there are also cases in which there are two or more types of proteins contained in the sample, or when there are two or more types of proteins contained in the sample. Even when the type of protein present in the sample is unknown, the total amount of protein in the sample can be measured with high accuracy. In addition, when measuring the absorption curve of the reagent of the present invention itself, the absorbance (blank value) at the protein measurement wavelength is low, which makes it possible to use a single-beam colorimeter even when the sample contains a large amount of protein. . The reagent of the present invention has various advantages as described above, and therefore, extremely good results can be obtained especially when quantifying a sample containing a low concentration of protein. In the reagent of the present invention, the active ingredient that changes the color tone is a known dye represented by the above formula (1), namely Coomassie Brilliant Blue (COOmassjeBril).
ljantB]Ue)G-250.
本発明試薬中に含有させるべき式(1)の染料の配合量
としては通常本発明試薬中に0.004〜0.02%(
w/v)、好ましくは0.008〜0.014%含有さ
れるように式(1)の染料を配合すればよい。本発明試
薬においてはメチルセノレロースが配合される。The amount of the dye of formula (1) to be contained in the reagent of the present invention is usually 0.004 to 0.02% (
The dye of formula (1) may be blended so that the amount (w/v), preferably 0.008 to 0.014%, is contained. The reagent of the present invention contains methylsenorelose.
メチルセルロースの配合量としては通常本発明試薬中に
0.01〜0.5%(w/v)、好ましくは0.01〜
0.1%、特に好ましくは0.01〜0.03%程度含
有されるようにメチルセルロースを配合すればよい。本
発明試薬中に配合される酸としては公知のものを広く使
用でき、具体的には過塩素酸、塩酸、硫酸、過沃素酸、
りん酸、亜りん酸、セレン酸、亜硫酸等の無機酸や蓚酸
、マレイン酸、、トリクロル酢酸、ジクロル酢酸等の有
機酸を例示できる。上記酸のうちPKaが0〜4の酸が
好ましく、PKaが1〜2の酸が特に好ましい。PKa
がO〜4の酸のうち過沃素酸、りん酸、亜りん酸、セレ
ン酸、亜硫酸、マレイン酸、蓚酸、ジクロル酢酸等が好
ましく、りん酸、蓚酸等が特に好ましい。本発明試薬の
液性は通常酸性であればよく、好ましくはそほのPHが
0.5〜2.\特に好ましくは0.7〜0.9である。
酸の配合量としては用いられる酸の種類により異なソー
概には言えないが、上記PHとなるように適宜配合すれ
ばよい。式(1)の染料、メチルセルロース及び酸は例
えば水性媒体、好ましくは水に添加される。The amount of methylcellulose contained in the reagent of the present invention is usually 0.01 to 0.5% (w/v), preferably 0.01 to 0.5% (w/v).
Methylcellulose may be blended in an amount of about 0.1%, particularly preferably about 0.01 to 0.03%. A wide range of known acids can be used as the acid to be mixed in the reagent of the present invention, and specifically, perchloric acid, hydrochloric acid, sulfuric acid, periodic acid,
Examples include inorganic acids such as phosphoric acid, phosphorous acid, selenic acid, and sulfurous acid, and organic acids such as oxalic acid, maleic acid, trichloroacetic acid, and dichloroacetic acid. Among the above acids, acids with a PKa of 0 to 4 are preferred, and acids with a PKa of 1 to 2 are particularly preferred. PKa
Among the acids having 0 to 4, periodic acid, phosphoric acid, phosphorous acid, selenic acid, sulfurous acid, maleic acid, oxalic acid, dichloroacetic acid, etc. are preferred, and phosphoric acid, oxalic acid, etc. are particularly preferred. The liquid nature of the reagent of the present invention should normally be acidic, preferably with a pH of 0.5 to 2. \Particularly preferably 0.7 to 0.9.
The amount of acid to be blended varies depending on the type of acid used, but cannot be generalized, but may be blended as appropriate to achieve the above pH. The dye of formula (1), methylcellulose and acid are added, for example, to an aqueous medium, preferably water.
これら成分の添加順序としては特に限定がなく、例えば
これらの成分を同時に水に添加してもよいし、これら成
分をそれぞれ水に添加した後これらを混合してもよい。
本発明試薬には試薬のPHを安定させるために通常の緩
衝剤を適量添加してもよい。There is no particular limitation on the order of addition of these components; for example, these components may be added to water at the same time, or these components may be added to water and then mixed.
An appropriate amount of a conventional buffer may be added to the reagent of the present invention in order to stabilize the pH of the reagent.
また本発明試薬には適当な溶媒、例えばメタノール、エ
タノール等の低級アルコール類、ジメチルスルホキシド
、ジメチルホルムアミド、ヘキサメチルリン酸トリアミ
ド等を適量添加してもよい。ノ 本発明試薬は広範囲の
異なるタイプの蛋白質に対して優れた感度を示す。Further, an appropriate amount of a suitable solvent such as lower alcohols such as methanol and ethanol, dimethyl sulfoxide, dimethyl formamide, hexamethyl phosphoric triamide, etc. may be added to the reagent of the present invention. The reagent of the present invention exhibits excellent sensitivity to a wide range of different types of proteins.
斯かる蛋白質としては例えばアルブミン(人血清アルブ
ミン、牛血清アルブミン)、グロブリン(人血清γ−グ
ロブリン、ウサギγ−グロブリン)、ヘモグロビン(牛
7ヘモグロビン)、キモトリプシノゲンA1α−キモト
リプシン、チトクロームC1α−アミラーゼ、カタラー
ゼ、フィブリノーゲン、ヒストン、ヘモシアニン、ペプ
シン、トランスフエリン、トリプシン等を挙げることが
できる。θ 本発明試薬を用いてサンプル中に含有され
ている蛋白質を定量するに際し、本発明試薬の使用量と
してはサンプル中の蛋白質の量によつて異なソー概には
言えないが、蛋白質が本発明試薬中の式(1)の染料に
より完全に捕捉されるような割合で本発明試薬を用いる
のがよい。Examples of such proteins include albumin (human serum albumin, bovine serum albumin), globulin (human serum γ-globulin, rabbit γ-globulin), hemoglobin (bovine 7 hemoglobin), chymotrypsinogen A1α-chymotrypsin, cytochrome C1α-amylase. , catalase, fibrinogen, histones, hemocyanin, pepsin, transferrin, trypsin, and the like. θ When quantifying the protein contained in a sample using the reagent of the present invention, the amount of the reagent of the present invention to be used varies depending on the amount of protein in the sample, but The reagent of the invention is preferably used in such a proportion that it is completely captured by the dye of formula (1) in the reagent.
例えば定量すべきサンプル中に蛋白質が0〜200μg
含有されている場合には0.004〜0.02%(w/
v)の染料を含有する本発明試薬を3〜5m1程度用い
るのがよい。本発明試薬は茶色に着色されているが、式
(1)の染料が蛋白質と結合すると本発明試薬とサンプ
ルとの混合液は青色に呈色される。For example, if there are 0 to 200 μg of protein in the sample to be quantified,
If contained, 0.004-0.02% (w/
It is preferable to use about 3 to 5 ml of the reagent of the present invention containing the dye of v). The reagent of the present invention is colored brown, but when the dye of formula (1) binds to protein, the mixture of the reagent of the present invention and the sample becomes blue.
蛋白質一染料錯体を含有する混合液は極めて安定であり
、該混合液を3時間以上という長時間に亘つて放置した
場合においても呈色度合は極めて変化しにくい。また蛋
白質一染料錯体の上記混合液中における濃度が増えるに
つれて青の呈色度合はより強くなる。それ故本発明試薬
とサンプルとの混合液の呈色度合を測定することにより
サンプル中に含有されている蛋白質を定量することがで
きる。該混合液の呈色度合を測定する方法としては特に
制限されず従来この分野て慣用されている方法を広く適
用できる。而して例えば分光光度計や585〜595n
mの領域の波長の吸収を測定できるような−比色計等の
光学機器により混合液の呈色度合を容易に測定できる。
より具体的には、例えば分光光度計により混合液の吸光
度を測定し、予め標準サンプルを用いて作成した検量線
からサンプル中に含有されている蛋白質の量を読み取る
ことができ,る。測定の際に用いられるスペクトルの波
長としては一般に585〜595nm1好ましくは59
0r1m程度とするのがよい。本発明では本発明試薬と
サンプルとを混合した後、この混合液を試料として分光
光度計による測定に用いることができる。本発明試薬は
尿、血清、髄液、食品、その他生物学的に誘導された液
体やこれらの抽出物中の蛋白質の検出に好適に用いられ
る。A liquid mixture containing a protein-dye complex is extremely stable, and the degree of coloration is extremely difficult to change even when the liquid mixture is left for a long time of 3 hours or more. Furthermore, as the concentration of the protein-dye complex in the above mixture increases, the degree of blue coloration becomes stronger. Therefore, by measuring the degree of coloration of the mixture of the reagent of the present invention and the sample, the protein contained in the sample can be quantified. The method for measuring the degree of coloration of the liquid mixture is not particularly limited, and methods conventionally used in this field can be widely applied. For example, a spectrophotometer or 585-595n
The degree of coloration of the liquid mixture can be easily measured using an optical instrument such as a colorimeter that can measure the absorption of wavelengths in the m range.
More specifically, for example, the absorbance of the mixed solution can be measured using a spectrophotometer, and the amount of protein contained in the sample can be read from a calibration curve prepared in advance using a standard sample. The wavelength of the spectrum used during measurement is generally 585 to 595 nm, preferably 59 nm.
It is preferable to set it to about 0r1m. In the present invention, after mixing the reagent of the present invention and a sample, this mixed solution can be used as a sample for measurement with a spectrophotometer. The reagent of the present invention is suitably used for detecting proteins in urine, serum, cerebrospinal fluid, foods, other biologically derived fluids, and extracts thereof.
以下に実施例を挙けて本発明をよソー層明らかにする。The present invention will be clearly explained with reference to Examples below.
尚実施例にて比較較のために用いられて3いるバイオ・
ラット●プロテイン●アツセイ●キット〔商標、バイオ
・ラット・ラボラトリイーズ社製〕は特開昭53−25
49吟公報に記載の試薬と同一のものであり、下記実施
例ではこの市販品を5倍に希釈し、次いでこれをろ過し
たもの(以下4これを1BRキット希釈液ョという)を
使用した。実施例1
精製水に蓚酸を添加し、3吟間加温攪拌後室温まで冷却
して1.9M/′の蓚酸水溶液を調製する。In addition, the three bio-chemicals used for comparison in the examples
Rat ● Protein ● Assay ● Kit [trademark, manufactured by Bio Rat Laboratories Co., Ltd.] is published in Japanese Patent Publication No. 53-25.
The reagent is the same as the reagent described in the 49th official publication, and in the following examples, this commercially available product was diluted 5 times and then filtered (hereinafter referred to as 1BR kit diluted solution). Example 1 Oxalic acid is added to purified water, heated and stirred for 3 minutes, and then cooled to room temperature to prepare a 1.9 M/' oxalic acid aqueous solution.
以下で使用する蓚酸水溶液は斯かる蓚酸水溶液の上澄で
ある。The oxalic acid aqueous solution used below is the supernatant of such an oxalic acid aqueous solution.
精製水を沸騰させ、最終濃度(本発明の蛋白質分析用試
薬中における濃度)が0.025W/■%となるように
メチルセルロース〔商標メトローズ60SH501信越
化学(株)製〕を加え、1紛間攪拌後等量の冷却した精
製水を加えてメチルセルロースノ水溶液を調製する。Boil purified water, add methylcellulose [trademark Metrose 60SH501 manufactured by Shin-Etsu Chemical Co., Ltd.] so that the final concentration (concentration in the reagent for protein analysis of the present invention) is 0.025 W/■%, and stir once. Then add an equal amount of cooled purified water to prepare an aqueous methylcellulose solution.
次に上記メチルセルロース水溶液75TrLLにクーマ
シイブリリアント ブルーG25O〔商標、シグマ社製
〕20m9を溶解し、この溶液に蓚酸水溶液75m1を
混合する。Next, 20 ml of Coomassie Brilliant Blue G25O (trademark, manufactured by Sigma Corporation) is dissolved in the above 75 TrLL aqueous methylcellulose solution, and 75 ml of an oxalic acid aqueous solution is mixed with this solution.
混合液を2回P過し、得られる沖液を本発明の蛋白質分
析用試薬とする。実施例2
実施例1の試薬3m1と標準サンプル(予め人血清アル
ブミンを0.1mg/ml〜1.0m9/Mtの割合と
なるように配合したもの)50Peとを混合する。The mixed solution is subjected to P-filtering twice, and the resulting Oki liquid is used as the reagent for protein analysis of the present invention. Example 2 3 ml of the reagent of Example 1 and 50 Pe of a standard sample (preliminarily mixed with human serum albumin at a ratio of 0.1 mg/ml to 1.0 m9/Mt) are mixed.
10分後に分光光度計〔ヒタチ12榛分光光度計、日立
製作所製〕を用い、590r1mの波長にて吸光度を測
定し検量線を作成する。After 10 minutes, the absorbance was measured at a wavelength of 590 r1m using a spectrophotometer (Hitachi 12 Haru spectrophotometer, manufactured by Hitachi, Ltd.), and a calibration curve was created.
得られる検量線を第1図に示す。次に正常人又は腎疾患
のある患者の尿を採取し、上記標準サンプルに代えて該
尿50Peを用いる以外は上記と同様にして吸光度を測
定する。The resulting calibration curve is shown in FIG. Next, urine from a normal person or a patient with renal disease is collected, and the absorbance is measured in the same manner as above except that the urine 50Pe is used instead of the standard sample.
尿は必要ならば測定濃度範囲内にある様に希釈しておく
。測定された吸光度及び検量線から尿中の蛋白質量を求
める。その結果を第1表に示す。実施例3実施例1の試
薬3m1と人血清アルブミン50mg/Deの割合で含
有するサンプル中50μlとを混合する。If necessary, dilute the urine to within the measurement range. The amount of protein in urine is determined from the measured absorbance and calibration curve. The results are shown in Table 1. Example 3 3 ml of the reagent of Example 1 and 50 μl of a sample containing human serum albumin at a ratio of 50 mg/De are mixed.
この混合は手で5回振盪することにより行なう。混合し
てから5分後〜3時間後における混合液の吸光度を59
0nmて測定する。混合後の時間と吸光度との関係を第
2図に示す。比較のためにBRキット希釈液5mLと人
血清アルブミン50m9/Dfの割合で含有するサンプ
ル100Peとを上記と同様にして混合し、吸光度を5
95nmて測定する。This mixing is done by hand shaking 5 times. The absorbance of the mixed solution 5 minutes to 3 hours after mixing is 59
Measure at 0 nm. FIG. 2 shows the relationship between time after mixing and absorbance. For comparison, 5 mL of BR kit diluted solution and 100 Pe of sample containing human serum albumin at a ratio of 50 m9/Df were mixed in the same manner as above, and the absorbance was adjusted to 5.
Measure at 95 nm.
混合後の時間と吸光度との関係を第3図に示す。第2図
及び第3図より次のことがわかる。FIG. 3 shows the relationship between time after mixing and absorbance. The following can be seen from Figures 2 and 3.
本発明試薬とサンプルとの混合により速やかにクーマシ
イ ブリリアント ブルーG25O一人血清アルブミン
錯体が生成する。該錯体を含有する混合液は3時間後に
おいても極めて安定であり、吸光度も一定している。こ
れに対してBRキット希釈液とサンプルとの混合液の場
合には、吸光度がほぼ一定している期間はわすかに混合
液の5 〜3紛間程度てあり、それ以降は時間の経過と
共に吸光度がかなり減少する。本発明試薬とサンプルと
の混合液の安定性はBRキット希釈液とサンプルとの混
合液のそれに比し6倍以上に優れたものである。Coomassie Brilliant Blue G25O single serum albumin complex is immediately produced by mixing the reagent of the present invention and the sample. The mixed solution containing the complex is extremely stable even after 3 hours, and its absorbance remains constant. On the other hand, in the case of a mixture of the BR kit diluted solution and the sample, the absorbance remains almost constant for only about 5 to 3 minutes of the mixed solution, and after that, as time passes, the absorbance remains almost constant. The absorbance decreases considerably. The stability of the mixture of the reagent of the present invention and the sample is 6 times or more superior to that of the mixture of the BR kit diluent and the sample.
実施例4
人血清アルブミンを含有するサンプル(サンプルと実施
例1の試薬との混合液中における濃度が18mg/dl
となるように人血清アルブミンを調製したもの)を50
p1すつ採取し、5検体を用異する。Example 4 A sample containing human serum albumin (concentration in the mixture of the sample and the reagent of Example 1 was 18 mg/dl)
human serum albumin prepared to give 50
Collect 1 sample and use 5 samples.
この5検体のそれぞれに実施例1の試薬3m1を加え、
手て5回振盪する。5分後に59011mの波長て吸光
度を測定する。Add 3ml of the reagent of Example 1 to each of these 5 samples,
Shake by hand 5 times. After 5 minutes, the absorbance is measured at a wavelength of 59011 m.
得られる結果を第2表に示す。まやた上記と同様にして
異なる濃度で人血清アルブミンを含有するサンプル(サ
ンプルと実施例1の試薬との混合液中における濃度が7
5m9/dlとなるように人血清アルブミンを調整した
もの)を用いる以外は上記と同様にして吸光度を測定す
る。結果を第2表に併せて示す。また人血清アルブミン
を含有するサンプル(サンプルとBRキット希釈液との
混合液中における濃度が18mg/dl又は75mg/
Deとなるように人血清アルブミンを調製したもの)1
00Peを採取すること及びBRキット希釈液5m1を
用いる以外は上記と同様にして吸光度を測定する。The results obtained are shown in Table 2. Samples containing human serum albumin at different concentrations in the same manner as above (the concentration in the mixture of the sample and the reagent of Example 1 was 7.
Absorbance is measured in the same manner as above, except that human serum albumin (adjusted to 5 m9/dl) is used. The results are also shown in Table 2. In addition, samples containing human serum albumin (concentration in the mixed solution of sample and BR kit diluent are 18 mg/dl or 75 mg/dl)
Human serum albumin prepared to become De) 1
Absorbance is measured in the same manner as above except that 00Pe is collected and 5 ml of BR kit dilution solution is used.
その結果を第3表に示す。第2表及び第3表におけるY
は検体を5回測定して得られる吸光度の平均値であり、
SDは標準偏差であり、またCVは次式により求められ
るばらつきである。The results are shown in Table 3. Y in Tables 2 and 3
is the average value of absorbance obtained by measuring the sample five times,
SD is the standard deviation, and CV is the variation determined by the following equation.
第2表及び第3表から次のことがわかる。The following can be seen from Tables 2 and 3.
本発明試薬を用いた場合には、低濃度及び高濃度におけ
るはらつき(CV)はそれぞれ1.3%、0.6%であ
り、これにし対してBRキット希釈液を用いた場合には
、低濃度及び高濃度におけるばらつき(CV)はそれぞ
れ4.7%、2.8%であり、本発明試薬を用いた場合
のばらつきはBRキット希釈液を用いた場合のそれに比
し極めて小さい。それ故上記結果は本発明試薬を用いる
とBRキット希釈液を用いる場合に比しより正確に蛋白
質含有量を定量し得ることを示している。実施例5
人血清アルブミンを含有するサンプル(サンプルと実施
例1の試薬との混合液中における濃度が18mg/De
となるように人血清アルブミンを調製したもの)を50
p′ずつ採取し、5検体を用意する。When the reagent of the present invention was used, the fluctuations (CV) at low and high concentrations were 1.3% and 0.6%, respectively, whereas when the BR kit diluted solution was used, The variation (CV) at low and high concentrations was 4.7% and 2.8%, respectively, and the variation when using the reagent of the present invention was extremely small compared to that when using the BR kit diluent. Therefore, the above results indicate that the protein content can be determined more accurately using the reagent of the present invention than when using the BR kit diluent. Example 5 A sample containing human serum albumin (concentration in the mixture of the sample and the reagent of Example 1 was 18 mg/De
human serum albumin prepared to give 50
Prepare 5 specimens by collecting 1 p' each.
この5検体のそれぞれに実施例1の試薬3Tntを加え
、次いでボルテツクスージエニー モデルK−556G
(VOltex−GENIEMOdelK−556G)
〔商標、サイエンテイフイツクインダストリイーズ イ
ンコーポレーテツド製〕を用いスピード目盛にて5秒間
攪拌し放置する。放置してから5分後の時点、3時間後
の時点及び3時間後に再びスピード目盛2にて5秒間攪
拌し次に5分間放置した時点において590r1mの波
長で吸光度を測定する。得られた結果を第4表に示す。
スピード目盛2に代えてスピード目盛5にて攪拌する以
外は上記と同様にして吸光度を測定する。得られる結果
を第5表に示す。またスピード目盛2に代えてスピード
目盛8にて攪拌する以外は上記と同にして**吸光度を
測定する。得られる結果を第6表に示す。また人血清ア
ルブミンを含有するサンプル(サンプルとBRキット希
釈液との混合液中における濃度が18mg/d′となる
ように人血清アルブミンを調整したもの)100μ′を
採取すること及びBRキット希釈液5m1を用いる以外
は上記と同様にしてスピード目盛2,5又は8にて攪拌
し、595nmの波長で吸光度を測定する。3Tnt of the reagent of Example 1 was added to each of these five samples, and then vortexed
(VOltex-GENIEMOdelK-556G)
[trademark, manufactured by Scientific Industries, Inc.], stir for 5 seconds on the speed scale and leave to stand. After 5 minutes, 3 hours, and 3 hours after the mixture was left to stand, the mixture was stirred for 5 seconds at speed scale 2, and the absorbance was measured at a wavelength of 590 r1m after the mixture was left to stand for 5 minutes. The results obtained are shown in Table 4.
The absorbance is measured in the same manner as above except that stirring is performed at speed scale 5 instead of speed scale 2. The results obtained are shown in Table 5. **Absorbance is measured in the same manner as above except that stirring is performed at speed scale 8 instead of speed scale 2. The results obtained are shown in Table 6. In addition, 100 μ' of a sample containing human serum albumin (human serum albumin was adjusted so that the concentration in the mixture of the sample and BR kit diluent was 18 mg/d') and the BR kit diluent were collected. Stir at speed scale 2, 5, or 8 in the same manner as above except for using 5 ml, and measure the absorbance at a wavelength of 595 nm.
スピード目盛2の攪・拌条件下に得られる結果を第7表
に、スピード目盛5の攪拌条件下に得られる結果を第8
表に、スピード目盛8の攪拌条件下に得られる結果を第
9表にそれぞれ示す。第4表乃至第9表に於ける測定条
件A,B及びCは次の通りである。The results obtained under stirring conditions of speed scale 2 are shown in Table 7, and the results obtained under stirring conditions of speed scale 5 are shown in Table 8.
The results obtained under stirring conditions of speed scale 8 are shown in Table 9, respectively. Measurement conditions A, B, and C in Tables 4 to 9 are as follows.
A:放置してから5分後に吸光度を測定
B:放置してから3時間後に吸光度を測定C:放置して
から3時間経過した時点で、再び 同一のスピード目盛
にて5秒間攪拌し次に 5分間放置してから吸光度を測
定第4表乃至第9表に示す結果から次のことが明らかで
ある。A: Measure the absorbance 5 minutes after leaving it to stand B: Measure the absorbance 3 hours after leaving it C: After 3 hours have passed, stir again at the same speed scale for 5 seconds and then After standing for 5 minutes, the absorbance was measured.The following is clear from the results shown in Tables 4 to 9.
ます第4表の測定条件A,B,Cにおける各吸光度(計
比個のデータ)から又、SDを求め、これらの値からC
V値を算出すると、C■(%)=3.3となる。From each absorbance (measurement ratio data) under measurement conditions A, B, and C in Table 4, calculate SD, and from these values, calculate C.
When the V value is calculated, C■ (%)=3.3.
また第5表、第6表、第7表、第8表及び第9表の測定
条件A,B,Cにおける各吸光度からそれぞれX,SD
を求めCV値を算出するとそれぞれ5.1,5.4,1
2.5,13.3,13.6となる。このように本発明
試薬を用いた楊合のCV値(3.3,5.1及ひ5.4
)はBRキット希釈液を用いた場合のCV値(12.5
,13.3及び13.6)に比し極めて小さく、このこ
とから本発明試薬とサンプルとの混合液が経時変化を受
けず長時間安定であることがわかる。次に第4表、第5
表、及び第6表の測定条件A,B,Cにおける各吸光度
(計45個のデータ)よりY=0.158.CD=0.
008が求まり、CV値を算出すると4.9となる。In addition, from each absorbance under measurement conditions A, B, and C in Tables 5, 6, 7, 8, and 9, X and SD
When the CV values are calculated, they are 5.1, 5.4, and 1, respectively.
2.5, 13.3, 13.6. In this way, the CV values of Yanghe using the reagent of the present invention (3.3, 5.1 and 5.4
) is the CV value (12.5) when using the BR kit diluent.
, 13.3 and 13.6), and this shows that the mixture of the reagent of the present invention and the sample is stable for a long time without being subject to changes over time. Next, Table 4 and 5
From the table and each absorbance under measurement conditions A, B, and C in Table 6 (45 pieces of data in total), Y=0.158. CD=0.
008 is found, and the CV value is calculated to be 4.9.
これに対して第7表、第8表及ひ第9表の測定条件A,
B,Cにおける各吸光度(計45個のデータ)よりY=
0.299、SD=0.039が求まり、CV値は13
.0となる。このことから本発明試薬を用いる場合の方
がBRキット希釈液を用いる場合に比し、サンプル中の
蛋白質含有量を極めわて正確に定量でき、また現在臨床
上要求される大量サンプルを簡便な流れ作業の作にてい
ち早く処理することができる。実施例6
人血清アルブミン、牛血清アルブミン、牛ヘモグロビン
又は人血清γ−グロブリンを種々の濃度て含有する標準
サンプルを調整する。In contrast, measurement conditions A in Tables 7, 8, and 9,
From each absorbance in B and C (45 pieces of data in total), Y=
0.299, SD=0.039 was found, and the CV value was 13
.. It becomes 0. Therefore, when using the reagent of the present invention, it is possible to quantify the protein content in a sample more accurately than when using the BR kit diluent, and it is also possible to easily handle large quantities of samples that are currently required clinically. It can be processed quickly in assembly line work. Example 6 Standard samples containing various concentrations of human serum albumin, bovine serum albumin, bovine hemoglobin, or human serum γ-globulin are prepared.
実施例1の試薬3mLに人血清アルブミンを含有する標
準サンプル50Peを加え5回振盪し、590nmの波
長で吸光度を測定し検量線を作成する。同様にして牛血
清アルブミン、牛ヘモグロビン、人血清γ−グロブリン
についても検量線を作成する。斯くして作成される検量
線を第4図に示す。またBRキット希釈液5m1に人血
清アルブミン.を含有する標準サンプル100p′を加
え5回振盪し、595nmの波長で吸光度を測定し検量
線を作成する。50 Pe of a standard sample containing human serum albumin is added to 3 mL of the reagent of Example 1, shaken five times, and the absorbance is measured at a wavelength of 590 nm to create a calibration curve. Similarly, calibration curves are created for bovine serum albumin, bovine hemoglobin, and human serum γ-globulin. The calibration curve thus created is shown in FIG. Also, add human serum albumin to 5ml of BR kit diluent. Add 100 p' of a standard sample containing 100p' and shake 5 times, measure the absorbance at a wavelength of 595 nm and create a calibration curve.
牛血清アルブミン、牛ヘモグロビンについても同様にし
て検量線を作成する。斯くして作成される検量線を第5
図に示す。 ;第4図及び第第5図に
おける・印を結ふ曲線は人血清アルブミンについての検
量線であり、A印を結ぶ曲線は牛血清アルブミンについ
ての検量線であり、Δ印を結ぶ曲線は牛ヘモグロビンに
ついての検量線であり、またX印を結ぶ曲線は人血清4
γ−グロブリンについての検量線である。第4図及び第
3図から次のことがわかる。Calibration curves are created in the same manner for bovine serum albumin and bovine hemoglobin. The calibration curve created in this way is
As shown in the figure. ; The curve connecting the / marks in Figures 4 and 5 is the calibration curve for human serum albumin, the curve connecting the A marks is the calibration curve for bovine serum albumin, and the curve connecting the Δ marks is the calibration curve for bovine serum albumin. This is the standard curve for hemoglobin, and the curve connecting the X marks is human serum 4
This is a calibration curve for γ-globulin. The following can be seen from FIGS. 4 and 3.
本発明試躍及びBRキット希釈液はいずれも各種蛋白質
と反応するが、本発明試薬の場合は各種蛋白質との反応
性がほぼ同程度であり、そのために各種蛋白質の検量線
の傾きが極めて近似している。それ故サンプル中に含有
されている蛋白質が1種であり且つその蛋白質種が明白
である楊合には本発7明試薬及びBRキット希釈液のい
ずれを用いても問題はないが、サンプル中に含有されて
いる蛋白質種が未知てある場合や含有されている蛋白質
種が2種以上である場合は、本発明試薬を用いることに
よりサンプル中に含有されている総蛋白質をθBRキッ
ト希釈液を用いる場合に比しより精度よく定量し得ると
いうことができる。実施例7
実施例1の試薬の390nm〜730r1mの波長にお
ける吸光度を測定し、吸収曲線を作成する。Both the reagent of the present invention and the diluted solution of the BR kit react with various proteins, but in the case of the reagent of the present invention, the reactivity with various proteins is almost the same, and therefore the slopes of the calibration curves of various proteins are extremely similar. are doing. Therefore, in cases where the sample contains only one type of protein and the type of protein is clear, there is no problem using either the reagent of the present invention or the BR kit diluent; If the protein species contained in the sample is unknown or if there are two or more protein species contained in the sample, the total protein contained in the sample can be extracted using the θBR kit diluent by using the reagent of the present invention. It can be said that quantification can be performed with higher accuracy than when using this method. Example 7 The absorbance of the reagent of Example 1 at a wavelength of 390 nm to 730 r1m is measured to create an absorption curve.
この吸5収曲線を第6図に示す。またBRキット希釈液
の410r1m〜700nmの波長における吸光度を測
定し、吸収曲線を作成する。この吸収曲線を第7図に示
す。第6図及び第7図から次のことがわかる。This absorption curve is shown in FIG. Further, the absorbance of the BR kit diluted solution at a wavelength of 410r1m to 700nm is measured to create an absorption curve. This absorption curve is shown in FIG. The following can be seen from FIGS. 6 and 7.
蛋白ノ質定量用波長における本発明の試薬自身の吸光度
(ブランク値)は、BRキット希釈液のそれに比し約1
ノ2である。このためにBRキット希釈液を用いて吸光
度を測定するに際し、ダブルビームの吸光光度計を使用
する場合には問題を生じないが、シングルビームの吸光
光度計を使用する場合で特に測定されるべきサンプル中
に含有される蛋白質濃度が高い場合には精度が悪くなる
。これに対して本発明試薬を用いる場合には、シングル
ビームの吸光光度計を使用する時でも極めて精度よくサ
ンプル中の蛋白質を定量することができる。実施例8
蒸留水適量を70℃に加熱し、次いでメチルセルロース
〔商標メトローズ60SH50、信越化学(株)製〕0
.4qを加えて攪拌し、更にクーマシイブリリアント
ブルーG25O〔商標、シグマ社製〕0.24q、濃塩
酸27.4m1及び無水酢酸ナトリウム7.38Vを加
えて攪拌後、蒸留水を加えて全量量を1eとする。The absorbance (blank value) of the reagent itself of the present invention at the wavelength for protein quantification is about 1 compared to that of the BR kit diluent.
No.2. For this reason, when measuring absorbance using the BR kit dilution solution, there is no problem when using a double-beam spectrophotometer, but it should be especially noted when using a single-beam spectrophotometer. Accuracy deteriorates when the protein concentration contained in the sample is high. On the other hand, when using the reagent of the present invention, it is possible to quantify proteins in a sample with extremely high accuracy even when using a single beam spectrophotometer. Example 8 An appropriate amount of distilled water was heated to 70°C, and then methylcellulose [trademark Metrose 60SH50, manufactured by Shin-Etsu Chemical Co., Ltd.] 0
.. Add 4q and stir, then add Coomassie Brilliant.
0.24 q of Blue G25O (trademark, manufactured by Sigma), 27.4 ml of concentrated hydrochloric acid, and 7.38 V of anhydrous sodium acetate are added and stirred, and then distilled water is added to bring the total volume to 1 e.
この混合液を更に攪拌し、一昼夜放置後沖過し、得られ
る胛液を本発明の蛋白質分析用試薬とする。上記で得ら
れる試薬の370r1m〜750r1mの波長における
吸光度を測定し、吸収曲線を作成する。This mixed solution is further stirred, left to stand for a day and night, and filtered, and the resulting liquid is used as the reagent for protein analysis of the present invention. The absorbance of the reagent obtained above at a wavelength of 370 r1m to 750 r1m is measured to create an absorption curve.
この吸収曲線を第8図に示す。比較例1
メチルセルロースの代りにTween−20〔和光純薬
(株)製〕を4mL又は400μeを用いる以外は、上
記実施例8と同様にして蛋白質分析用試薬を得る。This absorption curve is shown in FIG. Comparative Example 1 A reagent for protein analysis is obtained in the same manner as in Example 8 above, except that 4 mL or 400 μe of Tween-20 (manufactured by Wako Pure Chemical Industries, Ltd.) is used instead of methylcellulose.
得られる試薬の370r1m〜750r1mの波長にお
ける吸光度を測定し、吸収曲線を作成する。The absorbance of the obtained reagent at a wavelength of 370r1m to 750r1m is measured to create an absorption curve.
この吸収曲線を第9図に示す。比較例2
メチルセルロースの代わりにNONIDET−P一40
〔BITHESRARESERCHLab.製〕を4m
1又は400μ′を用いる以外は、上記実施例8と同様
にして蛋白質分析用試薬を得る。This absorption curve is shown in FIG. Comparative Example 2 NONIDET-P-40 instead of methylcellulose
[BITHESRARESERCH Lab. 4 m long
A reagent for protein analysis is obtained in the same manner as in Example 8 above, except that 1 or 400 μ' is used.
得られる試薬の370nm〜750r1mの波長におけ
る吸光度を測定し、吸収曲線を作成する。The absorbance of the obtained reagent at a wavelength of 370 nm to 750 r1m is measured to create an absorption curve.
この吸収曲線を第10図に示す。比較例3
メチルセルロースの代りにBrij35〔和光純薬(株
)製〕を4f1又は0.4yを用いる以外は、上記実施
例8と同様にして蛋白質分析用試薬を得る。This absorption curve is shown in FIG. Comparative Example 3 A reagent for protein analysis is obtained in the same manner as in Example 8, except that 4f1 or 0.4y of Brij35 (manufactured by Wako Pure Chemical Industries, Ltd.) is used instead of methylcellulose.
得られる試薬の370nm〜750nmの波長における
吸光度を測定し、吸収曲線を作成する。この吸収曲線を
第11図に示す。比較例4
メチルセルロースの代りにトリトンXlOO〔和光純薬
(株)製〕を4TrL1又は400μlを用いる以外は
、上記実施例8と同様にして蛋白質分析用試薬を得る。The absorbance of the obtained reagent at a wavelength of 370 nm to 750 nm is measured to create an absorption curve. This absorption curve is shown in FIG. Comparative Example 4 A reagent for protein analysis is obtained in the same manner as in Example 8, except that 4TrL1 or 400 μl of Triton XlOO (manufactured by Wako Pure Chemical Industries, Ltd.) is used instead of methylcellulose.
得られる試薬の370nm〜750nmの波長における
吸光度を測定し、吸収曲線を作成する。この吸収曲線を
第12図に示す。第8図〜第12図から次のことがわか
る。The absorbance of the obtained reagent at a wavelength of 370 nm to 750 nm is measured to create an absorption curve. This absorption curve is shown in FIG. The following can be seen from FIGS. 8 to 12.
蛋白定量用波長(590r1m)における本発明試薬自
身の吸光度(ブランク値)は低い。これに対して比較例
1〜4の蛋白質分析用試薬は590r1mで吸収が認め
られ、590nmにおける吸光度は著しく高くなる。従
つて比較例1〜4の蛋白質分析用試薬を用いてサンプル
中の蛋白質を測定する場合には、精度が著しく悪くなる
のを避け得ず、本発明の所期の効果が発輝され難くなる
。The absorbance (blank value) of the reagent of the present invention itself at the wavelength for protein quantification (590 r1m) is low. On the other hand, in the protein analysis reagents of Comparative Examples 1 to 4, absorption was observed at 590 r1m, and the absorbance at 590 nm was significantly high. Therefore, when measuring protein in a sample using the protein analysis reagents of Comparative Examples 1 to 4, it is unavoidable that the accuracy deteriorates significantly, making it difficult to achieve the desired effect of the present invention. .
第1図は本発明試薬を用いて測定した標準サンプル中の
蛋白質(人血清アルブミン)量と吸光度との関係を示す
図である。FIG. 1 is a diagram showing the relationship between the amount of protein (human serum albumin) in a standard sample and absorbance measured using the reagent of the present invention.
Claims (1)
として含有することを特徴とする蛋白質分析用試薬。 2 染料濃度が0.004〜0.02%(w/v)であ
り、メチルセルロースの濃度が0.01〜0.5%(w
/v)である特許請求の範囲第1項記載の試薬。 3 染料の濃度が0.008〜0.014%(w/v)
であり、メチルセルロースの濃度が0.01〜0.1%
(w/v)であり、酸がpKa0〜4の酸である特許請
求の範囲第1項記載の試薬。 4 pHが0.5〜2.5である特許請求の範囲第2項
又は第3項に記載の試薬。[Scope of Claims] 1. A reagent for protein analysis characterized by containing a dye represented by the formula ▲numerical formula, chemical formula, table, etc.▼, methylcellulose, and an acid as active ingredients. 2 The dye concentration is 0.004-0.02% (w/v), and the methylcellulose concentration is 0.01-0.5% (w/v).
/v). The reagent according to claim 1. 3 Dye concentration is 0.008-0.014% (w/v)
and the concentration of methylcellulose is 0.01-0.1%
(w/v) and the acid has a pKa of 0 to 4. 4. The reagent according to claim 2 or 3, which has a pH of 0.5 to 2.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14576879A JPS6049256B2 (en) | 1979-11-09 | 1979-11-09 | Shiyaku for protein analysis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14576879A JPS6049256B2 (en) | 1979-11-09 | 1979-11-09 | Shiyaku for protein analysis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5669556A JPS5669556A (en) | 1981-06-10 |
| JPS6049256B2 true JPS6049256B2 (en) | 1985-10-31 |
Family
ID=15392705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14576879A Expired JPS6049256B2 (en) | 1979-11-09 | 1979-11-09 | Shiyaku for protein analysis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6049256B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2071736A1 (en) * | 1991-06-24 | 1992-12-25 | Naoyuki Kouno | Acid dye staining method |
| CN103857690B (en) | 2011-08-19 | 2017-04-05 | 艾昆西恩斯公司 | protein detection |
-
1979
- 1979-11-09 JP JP14576879A patent/JPS6049256B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5669556A (en) | 1981-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Artiss et al. | Spectrophotometric study of several sensitive reagents for serum iron | |
| Doumas et al. | Albumin standards and the measurement of serum albumin with bromcresol green | |
| Palmer et al. | Automated determination of free amino groups in serum and plasma using 2, 4, 6-trinitrobenzene sulfonate | |
| Macart et al. | An improvement of the Coomassie Blue dye binding method allowing an equal sensitivity to various proteins: application to cerebrospinal fluid | |
| Hazra et al. | Protein determination with trinitrobenzene sulfonate: a method relatively independent of amino acid composition | |
| US5612223A (en) | Cyanide-free reagent and method for the determination of hemoglobin | |
| AU606283B2 (en) | Composition and method of assaying for trace amounts of proteins | |
| US3485587A (en) | Protein indicator | |
| JP4214271B2 (en) | Test piece for measuring creatinine | |
| Miyada et al. | Albumin quantitation by dye binding and salt fractionation techniques | |
| Fearon | The detection and estimation of uric acid by 2: 6-dichloroquinone-chloroimide | |
| WO1992011524A2 (en) | Reagent and methods for calcium determination | |
| JP2000193668A (en) | Composition for measuring trace amounts of protein | |
| Jung et al. | A microalbuminuria assay using bromphenol blue | |
| US3558278A (en) | Determination of albumin | |
| JP2749615B2 (en) | Novel indicator compounds, their preparation and use of the compounds in iron analysis systems | |
| JPS6049256B2 (en) | Shiyaku for protein analysis | |
| Kekki | Microdetermination of Amino Nitrogen as Copper Complexes a Modification for Plasma and Urine | |
| Sandhu | Serum phospholipids determined without acid digestion. | |
| Van Wilgenburg et al. | Criticism of the use of Coomassie Brilliant Blue G-250 for the quantitative determination of proteins | |
| JP3090503B2 (en) | Method for measuring protein | |
| GB2068541A (en) | Determination of chloride in serum | |
| JP5055507B2 (en) | Method and reagent for measuring protein in sample | |
| Klein et al. | Fluorometry of plasma amino nitrogen, with use of fluorescamine. | |
| JP4733596B2 (en) | Liquid reagent for measuring total protein in liquid samples |